Eszopiclone: An update on its use in insomnia

Drugs of Today

Volumn 47, Issue 4, 2011, Pages 263-275

  Owen, Richard T ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ESZOPICLONE; PLACEBO; ZOLPIDEM; ZOPICLONE;

AREA UNDER THE CURVE; BEDTIME DOSAGE; CHRONIC DISEASE; COGNITION; COMORBIDITY; DRUG ACTIVITY; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSGEUSIA; HEALTH CARE COST; HUMAN; INSOMNIA; JAPAN; MEMORY; POSITIVE END EXPIRATORY PRESSURE; PSYCHOMOTOR ACTIVITY; RECOMMENDED DRUG DOSE; REVIEW; SLEEP APNEA SYNDROME; TASTE DISORDER; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME;

ADULT; AGED; ANIMALS; AZABICYCLO COMPOUNDS; CLINICAL TRIALS AS TOPIC; COGNITION; DRUG APPROVAL; HUMANS; HYPNOTICS AND SEDATIVES; JAPAN; MEMORY; MIDDLE AGED; PIPERAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SLEEP APNEA, OBSTRUCTIVE; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 80052724357     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2011.47.4.1590792     Document Type: Review

References (49)

1. Roth, T. New developments for treating sleep disorders. J Clin Psychiatry 2001, 62(Suppl. 10): 3-4.
2. Ford, D.E., Kamerow, D.B. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA 1989, 262(11): 1479-84.
3. Ancoli-Israel, S., Roth, T. Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. I. Sleep 1999, 22(Suppl. 2): S347-53.
4. Ustun, T.B., Privett, M., Lecrubier, Y. et al. Form, frequency and burden of sleep problems in general health care: A report from the WHO Collaborative Study on Psychological Problems in General Health Care. European Psychiatry 1996, 11: S5-S10.
5. Ohayon, M. Epidemiological study on insomnia in the general population. Sleep 1996, 19(3 Suppl): S7-15.
6. Asnis, G.M., Chakraburtty, A., DuBoff, E.A. et al. Zolpidem for persistent insomnia in SSRI-treated depressed patients. J Clin Psychiatry 1999, 60(10): 668-76.
7. Najib, J. Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. Clin Ther 2006, 28(4): 491-516.
8. Monti, J.M., Pandi-Perumal, S.R. Eszopiclone: its use in the treatment of insomnia. Neuropsychiatr Dis Treat 2007, 3(4): 441-53.
9. Najib, J.S. Efficacy and safety of zopiclone ad eszopiclone in the treatment of primary and comorbid insomnia. In: GABA and Sleep: Molecular, Functional and Clinical Aspects, Vol. 24. J.M. Monti, S.R. Pandi-Perumal, H. Mohler (Eds.). Springer: 2010, 413-52.
10. Culy, C., Castaner, J., Bayes, M. Eszopiclone. Drugs Fut 2003, 28(7): 640-46.
11. Nutt, D.J., Stahl, S.M. Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. J Psychopharmacol 2010, 24(11): 1601-12.
12. Brunello, N., Cooper, J., Bettica, P., Maier, G., Nutt, D. Differential pharmacological profiles of the GABAA receptor modulators zolpidem, zopiclone, eszopiclone, and (S)-desmethylzopiclone. World Psychiatry [Int Congr World Psychiatr Assoc (April 1-4, Florence) 2009] 2009, 8(Suppl. 1): Abst PO2.152.
13. Nofzinger, E., Buysse, D.J., Moul, D., Hall, M., Germain, A., Price, J. Eszopiclone reverses brain hyperarousal in insomnia patients: Evidence from [18F]-FDG PET. Eur Neuropsychopharmacol [21st Congr Eur Coll Neuropsychopharmacol (ECNP) (Aug 30-Sept 3, Barcelona) 2008] 2008, 18(Suppl. 4): Abst P.1.e.008.
14. Electronic Medicines Compendium (eMC). Zopiclone 3.75mg Tablets Summary of Product Characteristics. http://www.medicines.org.uk/EMC/medicine/24285/SPC/ Zopiclone+3.75mg+Tablets./. Accessed April 5, 2011.
15. Lunesta U.S. Prescribing Information. http://www.lunesta. com/PostedApprovedLabelingText.pdf. Accessed April 5, 2011.
16. Brunello, N., Bettica, P., Maier, G., Nutt, D. Pharmacokinetics of (S)-zopiclone and (S)-desmethylzopiclone following dosing with zopiclone and eszopiclone. World Psychiatry [Int Congr World Psychiatr Assoc (April 1-4, Florence) 2009] 2009, 8(Suppl. 1): Abst PO2.149.
17. Rosenberg, R., Caron, J., Roth, T., Amato, D. An assessment of the efficacy and safety of eszopiclone in the treatment of transient insomnia in healthy adults. Sleep Med 2005, 6(1): 15-22.
18. Zammit, G.K., McNabb, L.J., Caron, J., Amato, D.A., Roth, T. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin 2004, 20(12): 1979-91.
19. Krystal, A.D., Walsh, J.K., Laska, E., Caron, J., Amato, D.A., Wessel, T.C., Roth, T. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double- blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003, 26(7): 793-9.
20. Erman, M.K., Zammit, G., Rubens, R. et al. A polysomnographic placebo-controlled evaluation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomnia. J Clin Sleep Med 2008, 4(3): 229-34.
21. McCall, W.V., Erman, M., Krystal, A.D., Rosenberg, R., Scharf, M., Zammit, G.K., Wessel, T. A polysomnography study of eszopiclone in elderly patients with insomnia. Curr Med Res Opin 2006, 22(9): 1633-42.
22. Scharf, M., Erman, M., Rosenberg, R., Seiden, D., McCall, W.V., Amato, D., Wessel, T.C. A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep 2005, 28(6): 720-7.
23. Walsh, J.K., Krystal, A.D., Amato, D.A. et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep 2007, 30(8): 959-68.
24. Ancoli-Israel, S., Krystal, A.D., McCall, W.V. et al. A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep 2010, 33(2): 225-34.
25. Roth, T., Walsh, J.K., Krystal, A., Wessel, T., Roehrs, T.A. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med 2005, 6(6): 487-95.
26. Fava, M., McCall, W.V., Krystal, A. et al. Eszopiclone coadministered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry 2006, 59(11): 1052-60.
27. Krystal, A., Fava, M., Rubens, R. et al. Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression. J Clin Sleep Med 2007, 3(1): 48-55.
28. Pollack, M., Kinrys, G., Krystal, A. et al. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry 2008, 65(5): 551-62.
29. Joffe, H., Petrillo, L., Viguera, A. et al. Eszopiclone improves insomnia and depressive and anxious symptoms in perimenopausal and postmenopausal women with hot flashes: a randomized, double-blinded, placebo-controlled crossover trial. Am J Obstet Gynecol 2010, 202(2): 171.e1-e11.
30. Soares, C.N., Joffe, H., Rubens, R., Caron, J., Roth, T., Cohen, L. Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial. Obstet Gynecol 2006, 108(6): 1402-10.
31. Dorsey, C.M., Lee, K.A., Scharf, M.B. Effect of zolpidem on sleep in women with perimenopausal and postmenopausal insomnia: a 4-week, randomized, multicenter, double-blind, placebo-controlled study. Clin Ther 2004, 26(10): 1578-86.
32. Roth, T., Price, J.M., Amato, D.A., Rubens, R.P., Roach, J.M., Schnitzer, T.J. The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Prim Care Companion J Clin Psychiatry 2009, 11(6): 292-301.
33. Vgontzas, A.N., Kales, A., Bixler, E.O. Benzodiazepine side effects: role of pharmacokinetics and pharmacodynamics. Pharmacology 1995, 51(4): 205-23.
34. Rosenberg, R., Roach, J.M., Scharf, M., Amato, D.A. A pilot study evaluating acute use of eszopiclone in patients with mild to moderate obstructive sleep apnea syndrome. Sleep Med 2007, 8(5): 464-70.
35. Lettieri, C.J., Quast, T.N., Eliasson, A.H., Andrada, T. Eszopiclone improves overnight polysomnography and continuous positive airway pressure titration: a prospective, randomized, placebo-controlled trial. Sleep 2008, 31(9): 1310-6.
36. Lettieri, C.J., Shah, A.A., Holley, A.B., Kelly, W.F., Chang, A.S., Roop, S.A. Effects of a short course of eszopiclone on continuous positive airway pressure adherence: a randomized trial. Ann Intern Med 2009, 151(10): 696-702.
37. Lettieri, C.J., Collen, J.F., Eliasson, A.H., Quast, T.M. Sedative use during continuous positive airway pressure titration improves subsequent compliance: a randomized, doubleblind, placebo-controlled trial. Chest 2009, 136(5): 1263-8.
38. Doty, R.L., Treem, J., Tourbier, I., Mirza, N. A double-blind study of the influences of eszopiclone on dysgeusia and taste function. Pharmacol Biochem Behav 2009, 94(2): 312-8.
39. Boyle, J., Trick, L., Johnsen, S., Roach, J., Rubens, R. Nextday cognition, psychomotor function, and driving-related skills following nighttime administration of eszopiclone. Hum Psychopharmacol 2008, 23(5): 385-97.
40. Vermeeren, A., Riedel, W.J., van Boxtel, M.P., Darwish, M., Paty, I., Patat, A. Differential residual effects of zaleplon and zopiclone on actual driving: a comparison with a low dose of alcohol. Sleep 2002, 25(2): 224-31.
41. Botteman, M.F., Ozminkowski, R.J., Wang, S., Pashos, C.L., Schaefer, K., Foley, D.J. Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: a decision analytical model. CNS Drugs 2007, 21(4): 319-34.
42. Snedecor, S.J., Botteman, M.F., Bojke, C., Schaefer, K., Barry, N., Pickard, A.S. Cost-effectiveness of eszopiclone for the treatment of adults with primary chronic insomnia. Sleep 2009, 32(6): 817-24.
43. Snedecor, S.J., Botteman, M.F., Schaefer, K., Sarocco, P., Barry, N., Pickard, A.S. Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder. J Ment Health Policy Econ 2010, 13(1): 27-35.
44. A phase II/III study of SEP-190 (eszopiclone) in patients with primary insomnia (NCT00770510). ClinicalTrials.gov Web site, Accessed April 8, 2011.
45. A phase III study of SEP-190 (eszopiclone) in patients with insomnia (NCT00770692). ClinicalTrials.gov Web site, Accessed April 8, 2011.
46. O'Toole, S.M., Sekula, L.K., Rubin, R.T. Pituitary-adrenal cortical axis measures as predictors of sustained remission in major depression. Biol Psychiatry 1997, 42(2): 85-9.
47. Nestler, E.J., Gould, E., Manji, H. et al. Preclinical models: status of basic research in depression. Biol Psychiatry 2002, 52(6): 503-28.
48. Hensley, P.L., Nadiga, D., Uhlenhuth, E.H. Long-term effectiveness of cognitive therapy in major depressive disorder. Depress Anxiety 2004, 20(1): 1-7.
49. Owen, R.T. Extended-release zolpidem: efficacy and tolerability profile. Drugs Today (Barc) 2006, 42(11): 721-7.